QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 mei-pharma-rebrands-to-lite-strategy-adopts-litecoin-as-100m-treasury-reserve-ticker-changes-to-lits-on-sept-11-2025

Lite Strategy Rebrand Aligns with Company's LTC Digital Asset Treasury Strategy Advised by GSR VenturesMEI Pharma, Inc. (NA...

 mei-pharma-chooses-not-bitcoin-not-ethereum-but-litecoin-as-treasury-asset

San Diego-based MEI Pharma (NASDAQ:MEIP) has acquired 929,548 Litecoin (CRYPTO: LTC) tokens, becoming the first U.S.-listed pub...

 us-stocks-likely-to-open-higher-despite-trump-administrations-hard-deadline-warning-for-tariffs--verizon-dominos-pizza-earnings-in-focus

U.S. stock futures were positive on Monday after ending mostly lower on Friday. Futures of major benchmark indices were higher.

 why-is-mei-pharma-stock-soaring-on-friday

MEI Pharma, Inc. (NASDAQ:MEIP) stock is trading higher on Friday, with a session volume of 35.64 million compared to the averag...

 first-strategy-now-mei-pharma-litecoin-joins-bitcoin-as-treasury-asset

MEI Pharma (NASDAQ:MEIP) has launched a $100 million Litecoin (CRYPTO: LTC) treasury program, backed by Titan Partners Group and

 mei-pharma-q3-gaap-eps-039-up-from-137-yoy

MEI Pharma (NASDAQ:MEIP) reported quarterly losses of $(0.39) per share. This is a 71.53 percent increase over losses of $(1.37...

 mei-pharma-q2-eps-040-up-from-166-yoy

MEI Pharma (NASDAQ:MEIP) reported quarterly losses of $(0.40) per share. This is a 75.9 percent increase over losses of $(1.66)...

 deal-dispatch-shell-unilever-and-more-are-on-the-sell-side-the-onion-makes-alex-jones-cry-foul

Evolent Health, Kronos Bio, Saint-Gobain, Shell and Unilever are on the sell-side this week. Benzinga's Deal Dispatch has t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION